April 20, 2026 9:45–10:03 AM
Broadway 3
Avast Therapeutics is developing first-in-class, non-invasive peptide therapeutics that safely cross the blood-brain barrier to restore mitochondrial function and protect neurons.
This breakthrough approach targets neurodegenerative diseases such as Parkinson’s and Alzheimer’s at their earliest stages, with the potential to halt disease progression and transform brain medicine.
